FACTBOX-Gilead dominates HIV/AIDS drugs market

Mon Jul 19, 2010 2:32am EDT

 July 19 (Reuters) - About two dozen different drugs are
approved to fight the human immunodeficiency virus that causes
AIDS. They are used in so-called cocktails to attack the virus
from several different directions.
 Californian upstart Gilead (GILD.O) has outflanked larger
rivals to dominate the HIV/AIDS sector, thanks to a
single-minded focus on producing convenient combination pills.
 The industry's giants are fighting back, with
GlaxoSmithKline (GSK.L) and Pfizer (PFE.N) joining forces last
year to create a new joint company for HIV called ViiV.
 Generic competition means sales of existing drugs are set to
peak at around $12 billion in 2012 before halving by 2019,
according to market research group Datamonitor, putting pressure
on manuacturers to deliver new medicines from their pipelines.
 Drug        Company              2009 sales    U.S. approval
 Truvada     Gilead (GILD.O)       $2.49 bln      2004
 Atripla     Gilead/Bristol        $2.38 bln      2006
 Reyataz     Bristol-Myers (BMY.N) $1.40 bln      2003
 Kaletra     Abbott Labs (ABT.N)   $1.37 bln      2000
 Epzicom     ViiV                  $855 mln       2004
 Isentress   Merck (MRK.N)         $752 mln       2007
 Viread      Gilead                $668 mln       2001
 Combivir    ViiV                  $665 mln       1997
 Prezista    J&J (JNJ.N)           $592 mln       2006
 Epivir      ViiV                  $542 mln       1995
 source: Thomson Reuters; U.S Food and Drug Administration
 (Reporting by Ben Hirschler)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.